{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:15:26Z","timestamp":1785795326736,"version":"3.56.0"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"52","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"China Mega-Project for Infectious Diseases","award":["2017ZX10203202"],"award-info":[{"award-number":["2017ZX10203202"]}]},{"name":"China Mega-Project for Infectious Diseases","award":["2013ZX10002005"],"award-info":[{"award-number":["2013ZX10002005"]}]},{"name":"China Mega-Project for Innovative Drugs","award":["2016ZX09101065"],"award-info":[{"award-number":["2016ZX09101065"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Glucocorticoid as the standard treatment of autoimmune hepatitis has been recommended with different doses. The purpose of this study is to compare the efficacy and safety of high and low doses for clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Medline, Embase, and Cochrane Library were searched until January 16th, 2019 for cohort studies or randomized controlled trials in patients with autoimmune hepatitis. Glucocorticoid 60\u200amg\/d or 1\u200amg\/kg\/d was defined as high dose and 40 to 50\u200amg\/d or 0.5\u200amg\/d as low dose. Outcome of interests includes the incidence of the biochemical remission, adverse event, and endpoint events. Double arcsine method with a random-effect model was used to combine the incidence. Potential heterogeneity was explored by meta-regression and subgroup analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Overall, 25 studies (3305 patients) were included, with 10 studies in the high dose group and 15 in low dose group. The biochemical remission rate in the high and low dose group was 0.79 (95% confidence interval [CI] [0.72, 0.85]) and 0.72 (95% CI [0.65, 0.78]), respectively. The incidence of endpoint events and adverse event in the high were slightly higher (0.03, 95% CI [0.02, 0.04]; 0.42, 95% CI [0.30, 0.53]) than that of the low dose group (0.01, 95% CI [0.00, 0.01]; 0.39, 95% CI [0.15, 0.63]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>For autoimmune hepatitis patients, 60\u200amg\/d or 1\u200amg\/kg\/d of glucocorticoid gives higher biochemical remission rate and higher incidence of endpoint events and adverse events.<\/jats:p><\/jats:sec>","DOI":"10.1097\/md.0000000000018313","type":"journal-article","created":{"date-parts":[[2019,12,26]],"date-time":"2019-12-26T20:38:40Z","timestamp":1577392720000},"page":"e18313","source":"Crossref","is-referenced-by-count":17,"title":["The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis"],"prefix":"10.1097","volume":"98","author":[{"given":"Chi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Wu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center of Digestive Diseases, Beijing Friendship Hospital, Capital Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Qin","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District"},{"name":"Peking University International Hospital, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Qiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Xicheng District"},{"name":"Peking University International Hospital, Beijing"},{"name":"The Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hepatol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1751-2980.12479","article-title":"Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015)","volume":"18","year":"2017","journal-title":"J Dig Dis"},{"key":"R4-20230915","first-page":"e014603","volume":"7","author":"Costello","year":"2017","journal-title":"Patient perceptions of glucocorticoid side effects: a cross-sectional survey of users in an online health community"},{"key":"R5-20230915","first-page":"191","volume":"53","author":"Lamers","year":"2010","journal-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-016-8583-2","article-title":"The management of autoimmune hepatitis patients with decompensated cirrhosis: real-world experience and a comprehensive review","volume":"52","author":"Wang","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00535-010-0316-3","article-title":"Clinicopathological features of severe and fulminant forms of autoimmune hepatitis","volume":"46","author":"Yasui","year":"2011","journal-title":"J Gastroenterol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/j.1572-0241.2002.06019.x","article-title":"Prevalence of autoimmune liver disease in Alaska Natives","volume":"97","author":"Hurlburt","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/00365521.2014.946083","article-title":"Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands","volume":"49","author":"van Gerven","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1440-1746.2010.06384.x","article-title":"Population-based epidemiology study of autoimmune hepatitis: a disease of older women?","volume":"25","author":"Ngu","year":"2010","journal-title":"J Gastroenterol Hepatol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1080\/00365520802130183","article-title":"Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study","volume":"43","author":"Werner","year":"2008","journal-title":"Scand J Gastroenterol"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1046\/j.1440-1746.2003.03165.x","article-title":"Epidemiology of autoimmune liver disease","volume":"18","author":"Feld","year":"2003","journal-title":"J Gastroenterol Hepatol"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand J Gastroenterol"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"151","author":"Liberati","year":"2009","journal-title":"Ann Intern Med"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R16-20230915","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jebm.12141","article-title":"The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review","volume":"8","author":"Zeng","year":"2015","journal-title":"J Evid Based Med"},{"key":"R17-20230915","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/jech-2013-203104","article-title":"Meta-analysis of prevalence","volume":"67","author":"Barendregt","year":"2013","journal-title":"J Epidemiol Community Health"},{"key":"R18-20230915","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R19-20230915","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/1469-0691.12494","article-title":"The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses","volume":"20","author":"Melsen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"R20-20230915","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"R21-20230915","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R22-20230915","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"R23-20230915","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.3748\/wjg.v24.i13.1410","article-title":"Potential triggering factors of acute liver failure as a frst manifestation of autoimmune hepatitis-a single center experience of 52 adult patients","volume":"24","author":"Buechter","year":"2018","journal-title":"World J Gastroenterol"},{"key":"R24-20230915","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/MPG.0000000000001125","article-title":"Clinical characteristics and prognosis in children and adolescents with autoimmune hepatitis and overlap syndrome","volume":"63","author":"Rodrigues","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R26-20230915","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"R27-20230915","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/hep.26290","article-title":"Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study","volume":"57","author":"Ngu","year":"2013","journal-title":"Hepatology"},{"key":"R28-20230915","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/hep.25658","article-title":"Long-term outcome of Japanese patients with type 1 autoimmune hepatitis","volume":"56","author":"Yoshizawa","year":"2012","journal-title":"Hepatology"},{"key":"R29-20230915","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1665-2681(19)31493-0","article-title":"Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis","volume":"11","author":"Landeira","year":"2012","journal-title":"Ann Hepatol"},{"key":"R30-20230915","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/hep.24141","article-title":"Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis","volume":"53","author":"Yeoman","year":"2011","journal-title":"Hepatology"},{"key":"R31-20230915","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"R32-20230915","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1478-3231.2005.01141.x","article-title":"Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy","volume":"25","author":"Seela","year":"2005","journal-title":"Liver Int"},{"key":"R33-20230915","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jped.2018.04.007","article-title":"Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes","volume":"95","author":"Porta","year":"2019","journal-title":"Jornal de Pediatria"},{"key":"R34-20230915","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00535-018-1444-4","article-title":"Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey","volume":"53","author":"Joshita","year":"2018","journal-title":"J Gastroenterol"},{"key":"R35-20230915","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jim\u00e9nez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"R36-20230915","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/1751-2980.12085","article-title":"Autoimmune hepatitis in southern Israel: a 15-year multicenter study","volume":"14","author":"Delgado","year":"2013","journal-title":"J Dig Dis"},{"key":"R37-20230915","first-page":"302","article-title":"Autoimmune hepatitis in children: experiences in a tertiary center","volume":"23","author":"Dehghani","year":"2013","journal-title":"Iran J Pediatr"},{"key":"R38-20230915","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0b013e3182602b20","article-title":"Autoimmune hepatitis in children in Eastern Denmark","volume":"55","author":"Vitfell-Pedersen","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R39-20230915","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1872-034X.2011.00812.x","article-title":"Risk factors associated with relapse of type 1 autoimmune hepatitis in Japan","volume":"41","author":"Yokokawa","year":"2011","journal-title":"Hepatol Res"},{"key":"R40-20230915","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1053\/j.gastro.2011.02.065","article-title":"Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center","volume":"140","author":"Hoeroldt","year":"2011","journal-title":"Gastroenterology"},{"key":"R41-20230915","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00365520903555861","article-title":"Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response","volume":"45","author":"Werner","year":"2010","journal-title":"Scand J Gastroenterol"},{"key":"R42-20230915","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1365-2036.2006.03013.x","article-title":"Clinical features of Japanese male patients with type 1 autoimmune hepatitis","volume":"24","author":"Miyake","year":"2006","journal-title":"Aliment Pharmacol Therap"},{"key":"R43-20230915","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1365-2036.2006.03104.x","article-title":"Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study","volume":"24","author":"Floreani","year":"2006","journal-title":"Aliment Pharmacol Therap"},{"key":"R44-20230915","first-page":"341","article-title":"Therapeutic effects of azathioprine in combination with low-dose prednisolone in patients with intractable autoimmune hepatitis type 1","volume":"55","author":"Takenami","year":"2001","journal-title":"Acta Med Okayama"},{"key":"R45-20230915","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1046\/j.1440-1746.2001.02615.x","article-title":"Long-term outcome of autoimmune hepatitis in children","volume":"16","author":"Saadah","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"key":"R46-20230915","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1136\/gut.2010.235259","article-title":"British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis","volume":"60","author":"Gleeson","year":"2011","journal-title":"Gut"},{"issue":"(Suppl 1)","key":"R47-20230915","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1590\/s0004-28032015000500002","article-title":"Brazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liver","volume":"52","author":"Bittencourt","year":"2015","journal-title":"Arq Gastroenterol"},{"key":"R48-20230915","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/hep.30205","article-title":"Flare of autoimmune hepatitis causing acute on chronic liver failure: diagnosis and response to corticosteroid therapy","volume":"70","author":"Anand","year":"2018","journal-title":"Hepatology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T05:46:46Z","timestamp":1722232006000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000018313"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":47,"journal-issue":{"issue":"52","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000018313","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}